Journal of Psychedelic Studies
February 4, 2021
R. Andrew Yockey, Keith A. King
64 citations
About 9.68% of US adults aged 18 and older have used psilocybin at some point in their lives, based on pooled 2015–2018 national survey data from over 168,000 people. Lifetime use varied by demographics, drug use history, and sexual identity; people identifying as bisexual reported higher rates of use. Nearly two-thirds of those who had ever used LSD, methamphetamine, or heroin also reported psilocybin use. These findings can guide harm reduction strategies and public health messaging.
Journal of Psychedelic Studies
June 26, 2019
R. Andrew Yockey, Keith A. King, Rebecca A. Vidourek
18 citations
LSD use is increasing among US adults. An analysis of 2017 national survey data identified psychosocial factors linked to lifetime use. Being male, African American or Hispanic, using alcohol, ecstasy, marijuana, inhalants, cocaine, or cigarettes before age 21, having suicidal thoughts, and enjoying or seeking risky activities were all associated with higher likelihood of LSD use. The findings may help health professionals address this growing trend.
Journal of Medicine Surgery and Public Health
August 25, 2025
R. Andrew Yockey
2 citations
Ibogaine, a psychoactive compound from the Tabernanthe iboga plant, shows promise for easing withdrawal symptoms, reducing cravings, and improving psychiatric symptoms in people with severe mental illness and co-occurring substance use disorders. However, safety concerns, especially heart function risks like QT interval prolongation and life-threatening arrhythmias, limit its clinical use. Key research priorities include large-scale randomized controlled trials with personalized dosing, safer synthetic alternatives, studies of its neurobiological effects, and tracking long-term outcomes to safely harness its potential.